Wayne Rothbaum's most recent trade in Iovance Biotherapeutics Inc was a trade of 100,000 Deferred Restricted Stock Unit done . Disclosure was reported to the exchange on March 1, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics Inc | Wayne Rothbaum | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 100,000 | 100,000 | - | - | Deferred Restricted Stock Unit | |
| Iovance Biotherapeutics Inc | Rothbaum Wayne | Director | Purchase of securities on an exchange or from another person at price $ 9.15 per share. | 20 Feb 2024 | 5,000,000 | 28,067,333 (22%) | 3% | 9.2 | 45,750,000 | Common Stock |
| Iovance Biotherapeutics Inc | Wayne Rothbaum | Director | Purchase of securities on an exchange or from another person at price $ 6.50 per share. | 02 Dec 2022 | 10,000,000 | 18,067,333 (14%) | 7% | 6.5 | 65,000,000 | Common Stock |
| Iovance Biotherapeutics Inc | Wayne Rothbaum | Director | Purchase of securities on an exchange or from another person at price $ 6.43 per share. | 31 May 2022 | 500,000 | 8,067,333 (6%) | 0% | 6.4 | 3,215,500 | Common Stock |
| Iovance Biotherapeutics Inc | Wayne Rothbaum | Director | Purchase of securities on an exchange or from another person at price $ 6.77 per share. | 31 May 2022 | 500,000 | 7,567,333 (5%) | 0% | 6.8 | 3,384,550 | Common Stock |